SAM
LENZ

Silvercrest Asset Management’s LENZ Therapeutics LENZ Stock Holding History

Silvercrest Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.59M Buy
283,206
+108,514
+62% +$1.52M 0.02% 495
2025
Q4 		$2.8M Buy
+174,692
New +$5.09M 0.02% 495

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Silvercrest Asset Management's LENZ Position: Q1 2026 in Review

Silvercrest Asset Management increased its LENZ Therapeutics (LENZ) stake by 62% in Q1 2026, buying an estimated $1.52M and bringing the position to 283,206 shares worth $2.59M. The position accounts for 0.02% of the portfolio, ranked #495.

Silvercrest Asset Management first reported a position in LENZ in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.8M in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Silvercrest Asset Management held 283,206 shares of LENZ Therapeutics worth $2.59M as of Q1 2026.
  • Silvercrest Asset Management bought 108,514 LENZ Therapeutics shares in Q1 2026, an estimated $1.52M.
  • LENZ Therapeutics made up 0.02% of Silvercrest Asset Management's portfolio in Q1 2026, its #495 holding.
  • Silvercrest Asset Management first reported a position in LENZ Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Silvercrest Asset Management's LENZ Therapeutics position peaked at $2.8M in Q4 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.